Canaccord Genuity Reiterates a 'Buy' on Heartware Int'l (HTWR); HVAD Moves Closer to FDA Approval - Accumulate Shares
Tweet
Share
E-mailGet Alerts HTWR Hot Sheet
Price: $57.98 --0%
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Heartware Int'l (NASDAQ: HTWR) price target of $95.00.
Analyst, Jason R. Mills, said, "After a long day of serious debate about the merits of HTWR’s HVAD, the FDA Circulatory Devices Panel voted definitively that the benefits of HVAD therapy for BTT patients outweighed the risks (9-2 in favor); proved reasonably safe (8-3 in favor) and effective (11-0 in favor). Based on the totality of information (i.e., discussion and final vote), coupled with our clinician survey data regarding HVAD expectations post-approval, we maintain our expectations for FDA approval timing (Sept.) and total revenue in 2012 and beyond."
"While the favorable vote for HVAD could drive some near-term weakness in Thoratec (Nasdaq: THOR)(HOLD) common, we surmise Thoratec does not come out of this panel in “bad shape” when one thinks about how they can – and likely will – position HM2 juxtaposed to HVAD approval."
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $69.27 yesterday.
Analyst, Jason R. Mills, said, "After a long day of serious debate about the merits of HTWR’s HVAD, the FDA Circulatory Devices Panel voted definitively that the benefits of HVAD therapy for BTT patients outweighed the risks (9-2 in favor); proved reasonably safe (8-3 in favor) and effective (11-0 in favor). Based on the totality of information (i.e., discussion and final vote), coupled with our clinician survey data regarding HVAD expectations post-approval, we maintain our expectations for FDA approval timing (Sept.) and total revenue in 2012 and beyond."
"While the favorable vote for HVAD could drive some near-term weakness in Thoratec (Nasdaq: THOR)(HOLD) common, we surmise Thoratec does not come out of this panel in “bad shape” when one thinks about how they can – and likely will – position HM2 juxtaposed to HVAD approval."
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $69.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Deere (DE) PT Raised to $585 at JPMorgan
- Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
